Proven Effective in Preventing Viremia and Reducing Lymphoid DepletionStudy Design 44 healthy, 4-week-old, mixed-breed commercial pigs Housed communally (vaccinates and controls commingled for the duration of the study) Pigs were selected based on serological results for PCV2 antibody titer Selected pigs were randomized into vaccine and control groups as follows: The study was blinded for observations, sampling, necropsies and lab sample evaluations Nasal swabs were collected on Day 0 post-vaccination to ensure there was no PCV2 infection in test animals prior to vaccination During the post-vaccination observation period, 1 control pig was removed from the study for reasons not related to vaccination (swollen joints) Pigs were vaccinated on Day 0 and challenged 6 weeks later (42 days) Results Daily rectal temperatures were measured from Day - 2 to Day 21/22 post-challenge No significant differences in body temperature and no clinical signs were noted, except for one control pig at 15 days post-challenge Compared to control group pigs, the vaccinated group had: A significantly lower percentage of viremic pigs A significantly lower percentage of pigs with moderate to severe lymphoid depletion A significantly lower percentage of pigs with moderate to severe histiocytic replacement A significantly lower percentage of pigs with medium to high levels of immunohistochemistry staining
